[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, Shimizu A, Hyodo M, Yasuda Y: Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP; 2010;11(1):36-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports.
  • CONTEXT: Although surgical resection is the only curative therapeutic option for recurrent or metachronous pancreatic carcinomas, most such cancers are beyond surgical curability.
  • We herein report on two rare cases of remnant pancreatectomy used to treat recurrent or metachronous pancreatic carcinomas.
  • CASE REPORTS: CASE#1 A 65-year-old male developed weight loss and diabetes mellitus 83 months after a pylorus-preserving pancreaticoduodenectomy followed by two years of adjuvant chemotherapy (5-fluorouracil plus leucovorin plus mitomycin C) for a pancreatic carcinoma in the head of the pancreas (stage IA).
  • An abdominal CT scan revealed a 3 cm tumor in the remnant pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant distal pancreatectomy was performed and a pancreatic carcinoma similar in profile to the primary lesion (stage IIB) was confirmed pathologically.
  • CASE#2 A 67-year-old male showed increased CA 19-9 levels 25 months after a distal pancreatectomy for a pancreatic carcinoma in the body of the pancreas (stage IA).
  • An abdominal CT scan revealed a cystic lesion in the cut end of the pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant proximal pancreatectomy with duodenectomy was performed and a metachronous pancreatic carcinoma (stage III) was confirmed pathologically.
  • CONCLUSION: Remnant pancreatectomy can be considered a treatment option for recurrent or metachronous pancreatic carcinomas.
  • FDG-PET can play a key role in detecting remnant pancreatic carcinomas.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Wang J, Jiang Y, Li J, Tian S, Ran W, Xiu D: Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res; 2009;28:88
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma.
  • BACKGROUND: To assess the feasibility and efficacy of using 125I seed implantation under intraoperative ultrasound guidance for unresectable pancreatic carcinoma.
  • METHODS: Fourteen patients with pancreatic carcinoma that underwent laparotomy and considered unresectable were included in this study.
  • Nine patients were pathologically diagnosed with Stage II disease, five patients with Stage III disease.
  • Fourteen patients were treated with 125I seed implantation guided by intraoperative ultrasound and received D90 of 125I seeds ranging from 60 to 140 Gy with a median of 120 Gy.
  • Five patients received an additional 35-50 Gy from external beam radiotherapy after seed implantation and six patients received 2-6 cycles of chemotherapy.
  • In this preliminary investigation, 125I seed implant provided excellent palliation of pain relief, local control and prolong the survival of patients with stage II and III disease to some extent.
  • [MeSH-major] Carcinoma / radiotherapy. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pancreas / pathology. Pancreas / radiography. Pancreas / ultrasonography. Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Dec 1;56(11):2563-8 [2864997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):759-63 [2984152.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Surg Gynecol Obstet. 1970 Jun;130(6):1049-53 [4192028.001]
  • [Cites] Cancer. 1983 Sep 1;52(5):808-13 [6191854.001]
  • [Cites] Ann Surg. 1984 Jan;199(1):1-5 [6419687.001]
  • [Cites] Pain Suppl. 1986;3:S1-226 [3461421.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):319-29 [3104244.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Ann Surg. 1988 Jun;207(6):648-54 [3389933.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2764-8 [7595736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1357-62 [16029793.001]
  • [Cites] Radiother Oncol. 2005 Jul;76(1):48-53 [15990186.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):399-403 [16680642.001]
  • [Cites] Ann Surg. 1984 Sep;200(3):289-96 [6205632.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1705-10 [7284971.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):709-14 [6244074.001]
  • [Cites] Am J Surg. 1978 Feb;135(2):185-91 [626289.001]
  • (PMID = 19545454.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radioisotopes
  • [Other-IDs] NLM/ PMC2715376
  •  go-up   go-down


3. Dickinson KJ, Gomez D, Lowe A, Gokhale JA, Ausobsky JR, Guillou PJ, Rahman SH: Carcinoma of the body of pancreas in evolution: an aggressive disease affecting younger patients? JOP; 2007;8(3):312-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the body of pancreas in evolution: an aggressive disease affecting younger patients?
  • CONTEXT: Pancreatic body carcinoma has a poor prognosis with advanced disease at presentation.
  • PARTICIPANTS: Thirty-one patients with pancreatic body carcinoma (median age at diagnosis 72 years; range 43-87 years).
  • There was a significantly (P=0.024) greater prevalence of more advanced tumours post MDT (stage IV: 15/23, 65.2%) than pre MDT (stage IV: 2/8, 25.0%).
  • Neither tumour markers nor liver biochemistry differentiated tumour stage.
  • Best supportive care was offered to 16 patients (51.6%) while 12 patients (38.7%) were suitable for chemotherapy: 2 out of 8 pre MDT (25.0%) and 10 out of 23 (43.5%) post MDT (P=0.433).
  • For stage III tumours, post MDT patients tended to be younger (median 59 years vs. 74.5 years, P=0.042).
  • Survival was not significantly increased after MDT introduction but chemotherapy offered significant survival benefit on multivariate analysis (P=0.042; hazard ratio: 0.39, 95% CI: 0.16-0.97).
  • CONCLUSION: The trend is towards increased prevalence of pancreatic body cancer and more advanced disease at presentation.
  • Chemotherapy was associated with a survival benefit, although the introduction of the MDT has not significantly altered disease management.
  • [MeSH-major] Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495360.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


Advertisement
4. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


5. Saif MW, Sviglin H, Carpenter M: Impact of ethnicity on outcome in pancreatic carcinoma. JOP; 2005 May;6(3):246-54
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of ethnicity on outcome in pancreatic carcinoma.
  • In pancreatic cancer, African Americans are thought to have a higher incidence and poorer prognosis than Whites.
  • PATIENTS: A total 645 pancreatic cancer patients were identified in the database, of which, 530 patients were eligible for this study and retained for the statistical analysis.
  • Overall, 132 patients out of 415 (31.8%) were seen in stage I, 61 (14.7%) in stage II, 105 (25.3%) in stage III, 117 (28.2%) in stage IV, while 115 patients (21.7%) had missing stage.
  • Overall, 125 (23.6%) received surgery alone, 54 (10.2%) surgery with chemotherapy, 5 (0.9%) surgery with external radiation therapy, 10 (1.9%) external radiation therapy alone, 68 (12.8%) chemotherapy alone, 58 (10.9%) chemo-external radiation therapy, and 210 (39.6%) no therapy.
  • There were more survivors in females (43/255, 16.9%) than in males (25/275, 9.1%; P=0.009), and females had significantly greater survival times as compared to males (P=0.022).
  • CONCLUSIONS: Pancreatic cancer is a disease of both ethnicities with a slight male predominance among Whites and female predominance among Blacks.
  • We did not find any significant difference in the treatment specific outcome and survival between Blacks and Whites.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / therapy. African Americans. European Continental Ancestry Group. Pancreatic Neoplasms / ethnology. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Characteristics. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15883475.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene; 2000 Dec 27;19(56):6642-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
  • Experimental studies performed prior to 1990 led to the widely held belief that matrix metalloproteinases (MMPs) produced by cancer cells are of critical importance in tumor invasion and metastasis.
  • Based on this evidence, the pharmaceutical industry produced several well tolerated, orally active MMP inhibitors (MMPIs) which demonstrated efficacy in mouse cancer models.
  • Phase III clinical trials initiated in 1997-98 using marimastat, prinomastat (AG3340), and BAY 12-9566 alone or in combination with standard chemotherapy in patients with advanced cancers (lung, prostate, pancreas, brain, GI tract) have recently been reported; no clinical efficacy was demonstrated.
  • Bayer and Agouron have discontinued their ongoing Phase III drug trials of MMPIs in advanced cancer.
  • In retrospect, the failure of MMPIs to alter disease progression in metastatic cancer might have been anticipated since MMPs appear to be important in early aspects of cancer progression (local invasion and micrometastasis) and may no longer be required once metastases have been established.
  • Our understanding of MMP pathophysiology in cancer has expanded considerably in the past 10 years.
  • (1) most MMPs in tumors are made by stromal cells, not carcinoma cells;.
  • (2) cancer cells induce stromal cells to synthesize MMPs using extracellular matrix metalloproteinase inducer (EMMPRIN) and cytokine stimulatory mechanisms; and (3) MMPs promote cell migration and the release of growth factors sequestered in the extracellular matrix.
  • MMPs have a dual function in tumor angiogenesis: MMP-2 and MT1-MMP are required in breaking down basement membrane barriers in the early stage of angiogenesis, while other MMPs are involved in the generation of an angiogenic inhibitor, angiostatin.
  • In spite of considerable recent progress in identifying multiple roles of MMPs in disease, our understanding of MMP function in cancer is far from complete (see Table 1).
  • (1) patients with early stage cancer;.
  • (2) the use of MMPIs along with chemotherapy;.
  • (3) the measurement of MMPs in tumor tissue and blood as a means of identifying patients who are more likely to respond to MMPI therapy; and (4) identification of biomarkers that reflect activation or inhibition of MMPs in vivo.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Matrix Metalloproteinase Inhibitors. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Design. Drug Evaluation, Preclinical. Humans. Matrix Metalloproteinases / chemistry. Matrix Metalloproteinases / physiology. Mice. Models, Biological. Neoplasm Metastasis. Neovascularization, Pathologic. Stromal Cells / enzymology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426650.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 75
  •  go-up   go-down


7. Malayeri R, Ghassemboland M, Ranjpoor F, Maadi A: Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma. Hematol Oncol Stem Cell Ther; 2008 Oct-Dec;1(4):221-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma.
  • BACKGROUND AND OBJECTIVE: The response rate and median survival with gemcitabine monotherapy, although considered the standard treatment for inoperable and metastatic pancreatic cancer, is relatively poor.
  • We tested the efficacy and toxicity of a chemotherapy protocol consisting of gemcitabine, 5-fluorouracil (5-FU) and leucovorin in patients with inoperable or metastatic pancreatic cancer, which was shown to improve median survival in a small phase II trial.
  • PATIENTS AND METHODS: Patients older than 18 years of age with histologically or cytologically confirmed adenocarcinoma of the pancreas and bidimensionally measurable disease, and who were chemotherapy- and radiotherapy-naïve, were treated with a chemotherapy protocol consisting of gemcitabine 1250 mg/m2 on day 1, 5-FU 450 mg/m2 and leucovorin 100 mg/m2 on days 1-3.
  • The treatment was repeated every 2 weeks.
  • RESULTS: In an-intention-to-treat analysis, of 37 patients with pancreatic cancer (27 males, 10 females) (67.6% stage IVb) there were 7 (18.9%) objective partial responses (95% confidence interval, 8.33% to 29), 14 (37.8%) patients had stable disease and 16 (43.2%) had progressive disease.
  • The median response time was 3 months (range, 1.5 to 7.0 months).
  • Median overall survival time was 6.5 months (range, 1.0 to 15.5 months).
  • The response to chemotherapy was not different between males and females (P = .971).
  • No grade III/IV toxicities were seen.
  • CONCLUSION: Despite our poor survival data, the combination of gemcitabine with 5-/FU and leucovorin is an active and well-tolerated regimen in patients with pancreatic cancer that merits further evaluation in prospective randomized studies.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058477.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Udaka T, Konishi Y, Waki N, Hayama M, Kubo M, Sogabe O, Maeda H, Mizuta M, Shirakawa K: [Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer]. Gan To Kagaku Ryoho; 2008 Jun;35(6):937-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer].
  • The feasibility and anti-tumor activity of gemcitabine (GEM) as postoperative adjuvant chemotherapy were evaluated retrospectively.
  • Between September 1998 and June 2007, patients with resected invasive pancreatic cancer (stage III, IVa, IVb) were given adjuvant chemotherapy with GEM (GEM group, n=10) or did not receive chemotherapy (n=11).
  • There was a significant difference in overall survival between the GEM group and the no-chemotherapy group (p=0.037), but there was no significant difference in disease-free survival between the two groups.
  • Adjuvant chemotherapy with GEM was feasible and showed a benefit in patients with invasive pancreatic cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633220.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Between 1987 and 2004, 111 patients underwent pancreatic resection against invasive ductal carcinoma of the pancreas in Wakayama Medical University Hospital.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Fallai C, Bolner A, Signor M, Gava A, Franchin G, Ponticelli P, Taino R, Rossi F, Ardizzoia A, Oggionni M, Crispino S, Olmi P: Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori; 2006 Jan-Feb;92(1):41-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx.
  • AIMS AND BACKGROUND: To compare conventional fractionation (CF) radiation therapy (RT), arm A, versus a split-course accelerated hyperfractionated schedule (S-AHF), arm B, versus CFRT plus concomitant chemotherapy (CT), arm C, in terms of five-year survival and toxicity for squamous cell tumors of the oropharynx.
  • METHODS AND STUDY DESIGN: Between January 1993 and June 1998, 192 previously untreated patients with stage III and IV oropharyngeal carcinoma (excluding T1N1 and T2N1) were enrolled in a multicenter randomized phase III trial (ORO 93-01).
  • In arms A and C, 66 to 70 Gy in 33 to 35 fractions was administered five days a week for six and a half to seven weeks.
  • In arm B, the dose delivered was 64 to 67.2 Gy in two fractions of 1.6 Gy every day, five days a week, with a planned two-week split at 38.4 Gy.
  • The 13 second tumors were equally distributed and were mainly correlated with tobacco and alcohol consumption (five lung, two esophagus, two oral cavity, one larynx, one pancreas, one hepatocarcinoma, one myeloma).
  • Arm C showed slightly more G3+ late side effects involving subcutaneous tissues and mucosa, although significant late sequelae were relatively uncommon and the mucosal side effects were mostly transient.
  • The occurrence of persistent G3 xerostomia was comparable in the three treatment arms.
  • CONCLUSIONS: The results obtained with the combination of CT and RT compared with RT alone did not reach statistical significance, but combined treatment almost doubled the five-year overall survival, relapse-free survival and locoregional control rate.
  • Patients with advanced squamous cell carcinomas of the oropharynx who are medically suitable for the combined approach should be treated with a combination of radiotherapy and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Risk Factors. Salvage Therapy. Survival Analysis. Time Factors. Treatment Failure. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683383.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Katsumata K, Tomioka H, Sumi T, Yamasaki T, Takagi M, Kato F, Suzuki Y, Aoki T, Koyanagi Y: Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. Int J Clin Oncol; 2003 Apr;8(2):110-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
  • A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres.
  • The patient was a 52-year-old woman who had undergone surgery for cancer of the head of the pancreas in October 1996.
  • She had stage III disease and was followed up as an outpatient on oral therapy with a combined uracil and tegafur preparation.
  • In October 2000, abdominal computed tomography (CT) scans detected multiple liver metastases.
  • After three more courses of this therapy, the patient developed bile duct necrosis and died of disseminated intravascular coagulation.
  • As her metastases were controlled for about 7 months, hepatic arterial infusion of mitomycin C and degradable starch microspheres appears to be useful for treating liver metastasis of pancreatic cancer, but careful attention should be paid to the risk of severe complications such as bile duct necrosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Duct Diseases / chemically induced. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / secondary. Doxorubicin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Starch / adverse effects
  • [MeSH-minor] Chemoembolization, Therapeutic / adverse effects. Chemoembolization, Therapeutic / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Necrosis. Neoplasm Staging. Pancreaticoduodenectomy / methods. Risk Assessment. Tomography, X-Ray Computed


12. Fahrig R, Quietzsch D, Heinrich JC, Heinemann V, Boeck S, Schmid RM, Praha C, Liebert A, Sonntag D, Krupitza G, Hänel M: RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients. Anticancer Drugs; 2006 Oct;17(9):1045-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients.
  • RP101 [(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)], which supports apoptosis and prevents the acquisition of chemoresistance, was tested in cultured human pancreatic tumor cells.
  • This was concomitant with an enhanced expression of lymphotoxins alpha and beta, natural killer cell transcript 4, tumor necrosis factor LIGHT/TNFSF-14, and intercellular adhesion molecule-1 in pancreas carcinoma cells.
  • These results encouraged us to investigate the effect of RP101 in pancreas cancer patients.
  • Here, we present data from two RP101 combination therapy schemes.
  • In a first pilot study, 13 patients in stage III and VI of the disease were treated with gemcitabine +cisplatin+RP101.
  • RP101 co-treatment enhanced remissions, survival and time to progression.
  • Median survival was 447 days, time to progression 280 days and the response rate 33%.
  • The data indicate that acquisition of chemoresistance was prevented and the antitumor efficacy of standard chemotherapy was improved.
  • To our knowledge, RP101 co-treatment is more efficient than any other regimen published.
  • [MeSH-major] Bromodeoxyuridine / analogs & derivatives. Pancreatic Neoplasms / drug therapy


13. Itoh Y, Fuwa N, Shinoda M: A case of esophageal carcinoma surgically treated after discontinuance of the simultaneous application of radiotherapy and chemotherapy with low doses of CDDP and 5-FU. Radiat Med; 2000 Jan-Feb;18(1):55-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of esophageal carcinoma surgically treated after discontinuance of the simultaneous application of radiotherapy and chemotherapy with low doses of CDDP and 5-FU.
  • The patient, a 69-year-old man with esophageal cancer, had a type 2 tumor in the Mt region, accompanied with an ulcer measuring 12 cm in the major axis.
  • The clinical stage of the lesion was T3N1M0 (stage III), and simultaneous therapy combining radiotherapy (2 Gy/day) with chemotherapy employing CDDP (6 mg/day) and 5-FU (300 mg/day) was started on October 21, 1996.
  • During treatment, tumor invasion into the gastric walls from lymph node metastasis was observed on endoscopy, and radiotherapy was discontinued at a total dose of 40 Gy to avoid the possibility of bleeding.
  • Although tumor invasion from lymph node metastasis in the lesser curvature of the stomach was observed in the pancreas, no remaining cancer cells were noted in the primary nest and metastasized lymph node, suggesting the usefulness of the simultaneous combined therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Esophagectomy. Esophagoscopy. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Pancreatic Neoplasms / secondary. Radiotherapy Dosage. Stomach Neoplasms / secondary. Stomach Ulcer / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10852656.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Arkosy P, Sasi SL, Enyedi A, Szántó J, András C, Sápy P: [Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy]. Magy Seb; 2005 Feb;58(1):29-33
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy].
  • [Transliterated title] Inoperábilis pancreas-carcinoma neo- adjuváns kemoterápiát követo kuratív sebészetének korai tapasztalatai.
  • In the treatment of pancreatic cancer only curative resection increases the life expectancy.
  • At the time of diagnosis most patients are in stage (TMN of pancreatic cancer UICC 1997) III or IV, thus curative resection cannot be performed.
  • Neo-adjuvant therapy shrinks the tumour in 60-70%, giving new hope for the patients.
  • In this paper authors present two cases of pancreatic cancer resections.
  • Palliative operations were performed in patients with inoperable pancreatic cancer.
  • Later neo-adjuvant chemotherapy was performed--in these cases it meant chemotherapy--and after that a second, this time curative procedure was performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Pancreatectomy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018598.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


15. Viúdez A, Rodríguez J, De La Cámara J, Salgado E, Chopitea A, Gil-Bazo I, García-Foncillas J, Valero J, Espinós J, Martin-Algarra S: Triplet therapy with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4252

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet therapy with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
  • : 4252 Background: To determine the activity and tolerance of gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
  • METHODS: Thirty-two patients with confirmed diagnosis of stage IV pancreatic carcinoma, with a median age of 60 years and ECOG performance of 0 to 2 (59.4% ECOG 1), received gemcitabine 800 mg/m<sup>2</sup> intravenously (iv) days 1 and 14, cisplatin iv 75 mg/m<sup>2</sup> day 1, leucovorin 500 mg/<sup>2</sup> iv days 1 and 14 and 5-fluorouracil (FU) 2600 mg/m<sup>2</sup> iv days 1 and 14.
  • 87 % of patients were chemotherapy naive.
  • 13 % of patients had received prior chemotherapy, including cisplatin (6.3%), gemcitabine (6.3%), FU (6.3%) or docetaxel (3.1%).
  • Grade III/IV leucopenia, neutropenia or anemia was found in 21.8 %, 37.5 % and 19.25 %, respectively.
  • Main non-haematological grade III/IV toxicities included asthenia (18.8 %) anorexia (12.5 %) and nausea (9.4 %).
  • 10 patients (31.3 %) progressed while on-therapy.
  • With a median follow-up of 25 months (range 5.6 to 52.83), the median time to progression was 4.67 months (95% CI: 3.61 to 5.73), and the median overall survival was 10.23 months (95% CI: 4.30 to 14).
  • CONCLUSIONS: The combination of gemcitabine, FU, leucovorin and cisplatin, has moderate activity in metastatic carcinoma of the pancreas at an expense of an acceptable toxicity profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Schuetz T, Marshall J, Kaufman HL, Safran H, Panicali D: Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):2564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer.
  • : 2564 Background: Recombinant pox viruses have been developed as therapeutic anti-tumor vaccines.
  • Twenty-two patients with advanced pancreatic cancer (Stage III or IV) were enrolled (20 with metastatic disease; all had received prior therapy).
  • CONCLUSIONS: All of the patients in the first study had metastatic disease at baseline and all had failed first-line chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015248.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Boadas J, Balart J, Capellà G, Lluís F, Farré A: Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy. Rev Esp Enferm Dig; 2000 May;92(5):316-25
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy.
  • OBJECTIVE: The ominous prognosis of pancreatic carcinoma (PC) has led to a nihilistic attitude among physicians, and to the need to develop better tools for diagnosis, staging and treatment.
  • The aim of this study was to analyze a series of patients with PC in order to determine stage-related survival, and to try to improve diagnostic and therapeutic strategies.
  • TNM stage and survival were calculated.
  • We also analyzed age, sex, time elapsed until diagnosis, diagnostic tests, size and location, cytologic pathology confirmation, number of patients undergoing surgery, and procedures used.
  • Time elapsed until diagnosis: 3 +/- 15.7 months.
  • TNM staging: stage I 13%; stage II 25%; stage III 20%; stage IV 42%.
  • Stage-related survival: stage I 14 months; stage II 6 months; stage III 4 months; stage IV 1 month.
  • In 55% of the patients surgery revealed a higher stage of disease than had been diagnosed preoperatively.
  • CONCLUSIONS: Diagnosis was made at a late stage in many patients.
  • Early diagnosis, preoperative staging and postoperative management should be improved in these patients, and surgery should be associated with complementary chemotherapy and/or radiotherapy.
  • [MeSH-major] Pancreatic Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10927931.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


18. Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G: Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol; 2010 Oct;33(5):461-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
  • BACKGROUND: Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support.
  • PATIENTS AND METHODS: A retrospective survey was carried out including 40 patients with stage III or IV gemcitabine-refractory pancreatic carcinoma.
  • Response evaluation criteria in solid tumors and National Cancer Institute common toxicity criteria were employed respectively for response and toxicity assessment.
  • The median time to progression was 3.7 (range, 1-6.5 months), and median overall survival was 6 months (range, 2-8.2 months).
  • A stabilization of performance status and a subjective improvement of cancer-related symptoms were recorded in 21 patients (52.5%).
  • No correlation has been found between length of time to progression during first-line chemotherapy and length of that reported in the second-line setting or objective response.
  • CONCLUSIONS: Data presented in this article demonstrate that the second-line FOLFIRI regimen are able to induce an objective response in a relatively small fraction of patients with gemcitabine-refractory adenocarcinoma of the pancreas.
  • The use of second-line chemotherapy should be carefully proposed to patients with good performance status or those who had a good response to first-line therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Drug-Related Side Effects and Adverse Reactions. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142727.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Sata N, Kurashina K, Nagai H, Nagakawa T, Ishikawa O, Ohta T, Oka M, Kinoshita H, Kimura W, Shimada H, Tanaka M, Nakao A, Hirata K, Yasuda H: The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg; 2009;16(4):485-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery.
  • BACKGROUND: Pancreatic carcinoma causes more than 20,000 deaths every year in Japan.
  • The role of (neo-) adjuvant chemotherapy for pancreatic carcinoma is still controversial.
  • METHODS: At the 34th Annual Meeting of the Japanese Society of Pancreatic Surgery in 2007, questionnaires were distributed regarding the use of (neo-) adjuvant chemo(radio)therapy for pancreatic carcinoma between 2001 and 2005.
  • There were a total of 1,846 cases of resected pancreatic carcinoma between 2001 and 2005.
  • The lesion was located in the head of the pancreas in 1,204 cases (71.7%), in the body in 353 cases (21.0%), and in the tail in 111 cases (6.6%).
  • Adjuvant chemotherapy (usually involving gemcitabine) was used in 66.0% of cases.
  • The use of adjuvant chemotherapy was found to improve the overall survival rate.
  • Interestingly, adjuvant chemotherapy only improved survival in late-stage (UICC stages IIB, III, and IV) but not early stage (IA, IB, and IIA) patients.
  • Survival was treatment duration-dependent, with patients who received more than 12 months of therapy having a 3-year survival rate of 51.2%.
  • CONCLUSION: This high volume retrospective data indicated the promising effect of gemcitabine-based adjuvant chemotherapy and the rational duration of adjuvant chemotherapy should be determined in the future prospective studies.
  • [MeSH-major] Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Health Surveys. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333537.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Wu J, Shao Y, Rong W, Shan Y, Gao J, Wu T: [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):497-500
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas].
  • OBJECTIVE: To improve the diagnosis and treatment of carcinoma of head of pancreas.
  • METHODS: A retrospective study was carried out to evaluate 178 patients suffering from carcinoma of head of pancreas.
  • RESULTS: Pain in the epigastrium and obstructive jaundice were observed in 70% and 74.2% of these 178 patients, both of which were of significance (P < 0.001) between stage I, II and stage III, IV disease.
  • Only 18% of patients had pain in the back, 81.3% of whom belonged to the stage IV category.
  • The detection rate of the tumor by B-ultrasound, CT and MRI were 74.2%, 87.3% and 85.5%, respectively.
  • The median survival time was 7 months in patients with unresectable tumor who received radiotherapy and/or chemotherapy.
  • By now, pancreaticoduodenectomy is still the only effective treatment for the carcinoma of head of pancreas and internal drainage is an important palliative measure.
  • [MeSH-major] Pain / etiology. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperglycemia / etiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485509.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Regine WF, John WJ, McGrath P, Strodel WE, Mohiuddin M: The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma. J Hepatobiliary Pancreat Surg; 2000;7(1):53-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
  • We evaluated the feasibility of dose escalation using external beam radiation therapy (RT) and 5-fluorouracil (5-FU) following pancreaticoduodenectomy for pancreatic carcinoma.
  • Fourteen patients who underwent pancreaticoduodenectomy for stage I-III adenocarcinoma of the pancreas received postoperative high-dose chemoradiation.
  • RT was given at 1.8-Gy daily fractions to total doses of 54 Gy for patients with negative surgical margins (n = 12), and 64.8 Gy for those with gross residual disease (n = 2).
  • All patients were able to complete the planned high-dose postoperative chemoradiation and none required a treatment break.
  • Two patients developed grade 3 (n = 1) or 4 (n = 1) subacute toxicity, all gastrointestinal-related.
  • Dose escalation of postoperative 5-FU chemoradiation following pancreaticoduodenectomy for pancreatic carcinoma is well tolerated.
  • Further dose-intensification of postoperative adjuvant therapy in these patients appears feasible and is being evaluated in a recently activated national trial.
  • [MeSH-major] Adenocarcinoma / therapy. Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Pancreatic Neoplasms / therapy. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Feasibility Studies. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Liver Neoplasms / secondary. Male. Middle Aged. Radiation Dosage. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10982592.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol; 2009 Nov 20;27(33):5513-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
  • PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer.
  • PATIENTS AND METHODS: Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status <or= 2 were recruited.
  • This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077).
  • CONCLUSION: On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Confidence Intervals. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Proportional Hazards Models. Quality of Life. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Time Factors. Treatment Outcome. United Kingdom

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Nov 20;27(33):5487-91 [19858387.001]
  • (PMID = 19858379.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G9900432
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM: Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest; 2004;22(4):505-14
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
  • PURPOSE: To assess the efficacy and toxicity of combination therapy with gemcitabine and docetaxel in patients with unresectable pancreatic carcinoma.
  • PATIENTS AND METHODS: Thirty-four patients with unresectable stage III, IVA, and IVB pancreatic carcinoma were eligible for this study.
  • Due to a high incidence of myelosuppression in this first group, the treatment schedule was modified in the remaining patients to gemcitabine 1,000 mg/m2 i.v. and docetaxel 40 mg/m2 i.v. on days 1 and 8 of a 21-day schedule.
  • Partial responses noted in the pancreas and a variety of metastatic sites were maintained for 4 to 12 months (median 6 months).
  • The median time to progression was 6 months, and median survival was 10.5 months.
  • CONCLUSION: The response and survival data reported here for combination therapy with gemcitabine and docetaxel are encouraging given the poor prognosis associated with unresectable pancreatic cancer.
  • These data suggest that gemcitabine plus docetaxel may be more effective than either agent alone in the treatment of pancreatic cancer and warrants further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Neutropenia / chemically induced. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565807.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


24. Oman M, Blind PJ, Naredi P, Gustavsson B, Hafström LO: Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. Eur J Surg Oncol; 2001 Aug;27(5):477-81
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV.
  • AIM: To explore the feasibility of intraperitoneal (IP) 5-fluorouracil (5-FU) and (IV) leucovorin for patients with advanced pancreatic carcinoma.
  • MATERIALS AND METHOD: Thirty patients (11 men), median age 65 (range 36-74 years), with a non-resectable pancreatic carcinoma in stage III (n=2) and IV (n=28) were treated with IP 5-FU 750-1000 mg/m(2)and leucovorin IV 100 mg/m(2)for 2 days every 3rd week.
  • Tumour effect was analysed with repeated computed tomography (CT) scans, performance status was estimated with Karnofsky's index (KI) and morphine consumption, and toxicity assessed using World Health Organization (WHO) criteria.
  • RESULTS: Median survival time was 7 months (range 0-21).
  • Regional and systemic toxicity: The treatment was well tolerated, with no grade III or IV complications or side-effects.
  • The median KI showed a minor reduction during treatment.
  • CONCLUSION: Intraperitoneal administration of 5-FU is feasible for patients with nonresectable pancreatic carcinoma.
  • The treatment can induce a temporary stabilization of tumour growth and eventually prolong survival without adverse effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antimetabolites, Antineoplastic / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Leucovorin / administration & dosage. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11504519.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement